Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common ...

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday. The company will aim to raise up to $170 million ...

Underwriters have a 30-day option to purchase extra 1.13 million shares from present owners at IPO price. Beta Bionics will ...

Beta Bionics Inc. kicked off the new year with plans for an initial public offering of 7.5 million shares “as soon as ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Subcutaneous Drug Delivery Devices Market To Reach USD 56.95 Billion By 2032, Growing At A CAGR Of 7.07% - SNS Insider Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and ...

Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States, underscoring a gradual ...

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 ...

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people ...